Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Location

Business Partnerships Office
Boundary Brook House
Churchill Drive
Headington
Oxford
OX3 7LQ

Paul Whyte

Senior Business Partnerships Manager

I support the two Oxford Biomedical Research Centres in their mission to undertake translational, bench-to-bedside research. Biomedical Research Centres are part of the Government’s initiative to improve the translation of basic scientific developments into clinical benefits for patients and to reinforce the position of the UK as a global leader in healthcare related research. The NIHR Biomedical Research Centre, Oxford is a partnership between Oxford University Hospitals NHS Foundation Trust and Oxford University with a focus on Precision Medicine, Technology and Big Data, Immunity and Infection and Chronic Diseases. The NIHR Oxford Health Biomedical Research Centre is a partnership between the Oxford Health NHS Foundation Trust and Oxford University and aims to bring the best science to the complex problems of mental disorders and dementia. My role is to promote and support collaborative partnerships between the life sciences industry and Oxford’s researchers and clinicians through strategic alliances, R&D collaborations, contract and clinical research and resource sharing.

I joined the Business Partnerships Office in January 2015 and hold a PhD in immunology and an MBA.  Previously, I held commercial management and business development roles in biopharma and medtech companies with responsibilities for partnering and alliance management.  I have also raised private equity and non-dilutive funding as a CEO for life science companies.